News and Announcements
Shivom Successfully Raised $33 Million in the Private and Pre-sale Round and is Now Only $2 Million Away From Reaching Hardcap
- Published April 29, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Key Takeaways:
- Shivom’s Presale has now closed
- Closed the sale with 33 $ million dollars
- Main crowdsale that begins on May 3rd
Shivom’s Presale has now closed and we cannot thank you enough for making it an overwhelming success! We closed the sale with 33 $ million dollars and are now all geared up for the main crowdsale that begins on May 3rd, 2018 (next week!) We are now one step closer to achieving our targets and we couldn’t have reached this far without your continued support.
The success of our presale is a great encouragement for us to keep striving to reach our goals of building the world’s best platform to improve the global healthcare system. With your continued supportwe are well on our way to begin developing our platform for safe and secure DNA sequencing and data storage and sharing for advancement of precision medicine.
Shivom’s Journey
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
